Article
London-The Early Manifest Glaucoma Trial (EMGT) provides a unique set of data for the natural history of moderate glaucoma and demonstrates that lowering IOP by 25% protects against progression of visual field loss, according to Roger A. Hitchings, MD.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.